Prevention of Drug Deaths

Patricia Ferguson Excerpts

Thursday 27th March 2025 Westminster Hall

[Patricia Ferguson (Glasgow West) (Lab)]

It is a pleasure to serve with you in the chair, Dr Murrison. I congratulate the hon. Member for Strangford (Jim Shannon) on securing a debate on this important subject. I associate myself with the comments of my hon. Friend the Member for West Dunbartonshire (Douglas McAllister) about Christina McKelvie. I served in the Scottish Parliament with Christina for some 10 years, and she was, perhaps ironically, a real lover of life and a force for good.

I will focus on the Scottish Affairs Committee’s ongoing inquiry into the operation of the safer drug consumption facility in Glasgow, which is the first of its kind in the UK. My contribution will be entirely factual, as I do not want to prejudice the inquiry in any way, or to pre-empt any decisions the Committee may make. It is an important issue and relevant to this debate.

To give some context to the rationale for the safer drug consumption room: Scotland has the highest number of drug deaths in Europe by some margin. The data tell us that some 1,172 people died in 2023 alone, which was up by 121 on the previous year. Much of the action that can be taken to address this problem comes under the powers of the Scottish Government, but that, of course, does not include issues arising from the Misuse of Drugs Act 1971.

The Scottish Government have introduced a variety of measures, but I am speaking specifically about the safer drug consumption space. There are now some 200 such facilities in 12 countries around the globe, and the Scottish Parliament’s information centre explains that:

“Several long-term evaluations indicate that attendees of SDCFs engage safer injecting practices and reduce public injecting, leading to significant declines in HIV and Hepatitis C transmission and fewer ambulance callouts for overdoses.”

The idea of such a facility in Glasgow was first raised more than 10 years ago, but a variety of issues, including the reluctance of the then Lord Advocate, meant that the pilot facility opened in Glasgow only in January 2025, following considerable public engagement and after the current Lord Advocate provided a statement of prosecution policy. Although the possession of drugs remains a criminal offence, the Lord Advocate has indicated that it would not be in the public interest to prosecute users of the facility for simple possession offences, subject to certain limitations. I stress that this applies only to the facility.

Last month the Scottish Affairs Committee visited the Thistle, as the Glasgow facility is known, and we saw for ourselves what was on offer. Users have access to a shower and can receive treatment for wounds and other health issues associated with their addiction. Discrete spaces where users can inject are also available, and staff can offer clean needles. Users bring their own drugs, but staff can give advice when they become aware that a particularly strong or pure drug might be in circulation, so that users are aware of potential dangers. Clients can choose to stay at the centre for a time after injecting. So far, two overdoses have occurred on the premises, but they were dealt with either on site or in other locations, and both individuals made a recovery. Staff can also signpost clients to other services.

Since the Thistle opened in January, there have been over 140 unique service users, more than 1,000 visits, more than 700 injecting episodes managed on site, and the prevention of some 700 to 800 items of drug-related litter in public spaces in the vicinity of the centre. Eighty per cent of the clients are male.

The Thistle is a pilot scheme and will be carefully reviewed and analysed over the next three years to ascertain whether it has helped to reduce bloodborne viruses and other drug-related harms and death. It has become clear to the Committee that the staff working at the Thistle are dedicated, committed, welcoming and non-judgmental. I encourage Members to look out for our report when it is published.

Oral Answers to Questions

Patricia Ferguson Excerpts

Tuesday 25th March 2025 Commons Chamber

[Wes Streeting]

The Chancellor took almost immediate action to deliver the uplift in pay for NHS staff that they deserve. We are working closely with the Royal College of Nursing, Unison and others ensure that we tackle the challenges of low pay in the nursing profession that the hon. Member describes.

[Patricia Ferguson (Glasgow West) (Lab)]

T5. Since being elected, I have been contacted by a number of constituents registered with a GP in Scotland who find themselves unable to get medication for which they have a prescription while visiting England. Will my hon. Friend take steps to encourage NHS England and NHS Scotland to work together to find a solution that works for patients?

[The Minister for Care (Stephen Kinnock)]

I am very sorry to hear about my hon. Friend’s constituents’ experience. Accessing vital medicines while travelling between nations should be seamless, and I will ask NHS England to work with NHS Scotland to better understand what needs to change to make things easier for patients across the UK.

Rare Cancers Bill

Patricia Ferguson Excerpts

2nd reading
Friday 14th March 2025 Commons Chamber

[Patricia Ferguson (Glasgow West) (Lab)]

I thank my hon. Friend the Member for Edinburgh South West (Dr Arthur) for bringing forward this Bill. If, as we always say, politics is the language of priorities, then my hon. Friend has got his absolutely correct. I thank all Members who have shared their experiences and their stories, some incredibly moving. They should be what inspires us to take forward all the action we are proposing today.

I was struck by the fact that the hon. Member for Wokingham (Clive Jones) and I have something in common, which we probably would not want to have in common, in that we were both diagnosed with breast cancer in 2008. I have to say, my breast cancer was a strange breast cancer, and it always feels slightly strange talking about it, because no one’s ever heard of it. It is not a rare cancer as such, because it is a breast cancer, although there are some who argue it is actually a soft tissue sarcoma—whatever, it was treated as a breast cancer. It is called a phyllodes tumour.

Unlike other breast tumours, phyllodes tumours do not go into the ducts, but into the connective tissue. It presents differently from other cancers of the breast, and the treatment is also different, in that the only treatment that works is excision. Excision can be anything from a lumpectomy to a mastectomy. The hope is that there are clear margins, which mean the patient will be okay, but—and it is a big “but”—when a malignant phyllodes tumour is present, it can spread, and it can be difficult or impossible to treat. That is when it becomes a very different outcome.

I mention it today not because it is a rare cancer, but because it can be difficult to diagnose. It does not show up in a mammogram, for example, and there is no definitive explanation why such tumours occur. Some research is going on just now, but it is not conclusive as yet. A lot more work needs to happen, and because incidence is so low, it is difficult to research. The things we know about it for certain seem random to me. They tend to occur more often in the left breast. Why? I have no idea. They usually occur when a patient is in their 40s. As I have said, they do not seem to respond to chemo or radiotherapy, and they are not thought to be genetic or hormonal.

The reason I mention my case is that it can be a lonely thing to have an unusual cancer. When trying to explain it to family and friends, you say, “No, it did not show up in a mammogram. No, I am not getting chemotherapy or radiotherapy. No, I do not know why it happened. No, I had not heard of it either.” You begin to doubt yourself a little, and you begin to question what is actually going on. For someone with a very rare cancer, it must be incredibly difficult when there is not a background of research, not anything that they can read, and no one can give them a pamphlet about it and tell them what is happening.

It seems to me that we should know more about cancer full stop. We have got to 2025, and we know some things about cancer. We know how to treat some cancers, but there are so many others that we do not have the answer for. We need people to be diagnosed more quickly, which means that we have to have the research. We need people to have the best possible treatment, which means we have to look at the drugs and find out what works and what does not work, and where a drug can be transferred from one thing to another successfully. Crucially, we have to know why it is that some people get cancer and others do not.

This Bill will make a huge difference to the lives of some of the people we have heard about today. For some, as we know, it will not be soon enough. It is the responsibility of every single one of us to make change happen, and we have an opportunity today to take that step forward. My hon. Friend the Member for Mitcham and Morden (Dame Siobhain McDonagh) spoke about her sister, Margaret, who I worked with for a time in the Labour party. While I was listening to the other speeches, I was reflecting on what my hon. Friend said. I think we all need to be angry. We need to say—to shout it from the rooftops—that change begins today.

[Madam Deputy Speaker (Ms Nusrat Ghani)]

That was very powerful. I call Leigh Ingham.